Lancovutide

Summary

Lancovutide is an inhaled cyclic peptide antibiotic-derived compound originally isolated from Streptomyces lividans, investigated for the treatment of cystic fibrosis. It promotes hydration of airway surface liquid by stimulating chloride secretion and inhibiting sodium hyperabsorption, offering a mutation-agnostic approach to CF management. Clinical development has progressed through Phase II trials.

Mechanism of Action

Lancovutide (formerly MOLI1901) is a cyclic peptide that activates chloride secretion via calcium-activated chloride channels (CaCC) and inhibits sodium absorption through ENaC in airway epithelia, thereby improving mucociliary clearance in cystic fibrosis patients independent of CFTR mutation type.

Routes of Administration

Goals & Uses

• Airway surface liquid hydrationRespiratory / PharmacodynamicModerate
• Mutation-agnostic CF therapyTherapeutic PositioningModerate
• Improvement of mucociliary clearance in cystic fibrosisRespiratory / Disease ManagementModerate

Contraindications

• Severe bronchospasm or reactive airway diseaseRespiratoryModerate
• Known hypersensitivity to lancovutide or duramycinAllergyHigh

Adverse Effects

• CoughRespiratoryCommonPersistent or episodic cough
• HemoptysisRespiratoryRare
• BronchospasmRespiratoryUncommon
• Dysgeusia (altered taste)SensoryUncommon
• Throat irritationLocal / RespiratoryCommon

Drug Interactions

• Bronchodilators (e.g., salbutamol)Low
• Inhaled tobramycinLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patients under 6 yearsAgeRelative
• Renal or hepatic impairmentOrgan DysfunctionRelative

Regulatory Status

• European UnionInvestigationalOrphan medicinal product designation granted by EMA for cystic fibrosis. Not approved.
• United StatesInvestigationalOrphan Drug Designation granted by FDA for cystic fibrosis. Not approved for marketing.

Lancovutide has received Orphan Drug Designation in the US and EU for cystic fibrosis. It has not received full marketing approval in any jurisdiction as of the knowledge cutoff.

Evidence & Sources

No sources recorded yet.